A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

缬沙坦 医学 心力衰竭 射血分数 内科学 心脏病学 安慰剂 临床终点 血管紧张素受体 血管紧张素II 随机对照试验 血压 替代医学 病理
作者
Jay N. Cohn,Gianni Tognoni
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:345 (23): 1667-1675 被引量:2871
标识
DOI:10.1056/nejmoa010713
摘要

Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure; 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SICHEN发布了新的文献求助10
1秒前
大模型应助程公子采纳,获得10
2秒前
zhao完成签到,获得积分10
2秒前
旺仔同学发布了新的文献求助10
3秒前
RX信完成签到,获得积分10
4秒前
mumufan完成签到,获得积分10
4秒前
无花果应助晴云采纳,获得10
4秒前
啊标完成签到,获得积分10
4秒前
耕牛热完成签到,获得积分10
4秒前
bsn完成签到 ,获得积分10
5秒前
Akim应助乌拉拉采纳,获得10
6秒前
夏傥完成签到,获得积分10
7秒前
7秒前
彭博完成签到 ,获得积分10
8秒前
SICHEN完成签到,获得积分10
8秒前
韩_完成签到,获得积分10
9秒前
nnnnn完成签到 ,获得积分10
10秒前
鉨汏闫完成签到,获得积分10
10秒前
10秒前
mahliya完成签到,获得积分10
11秒前
耕牛热发布了新的文献求助10
11秒前
天天快乐应助zzz采纳,获得10
12秒前
整齐的白凡完成签到,获得积分10
12秒前
坐雨赏花完成签到 ,获得积分10
12秒前
查理fofo完成签到,获得积分10
14秒前
Shandongdaxiu完成签到 ,获得积分10
16秒前
丘比特应助旺仔同学采纳,获得10
16秒前
科研通AI2S应助旺仔同学采纳,获得10
16秒前
Jasper应助旺仔同学采纳,获得10
16秒前
量子星尘发布了新的文献求助10
16秒前
16秒前
小二郎应助坚强莺采纳,获得10
16秒前
17秒前
火星上的糖豆完成签到,获得积分10
17秒前
时尚战斗机应助sl采纳,获得10
17秒前
18秒前
zz完成签到,获得积分10
18秒前
非凡梦完成签到,获得积分10
18秒前
晴云发布了新的文献求助10
20秒前
dddd完成签到 ,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029